Foley & Lardner LLP
Compositions for therapeutics, targeted PET imaging and methods of their use
Described herein is a chelator for radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1, the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5. Such a bifunctional ligand can eliminate (e.g., 89Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.
Memorial Sloan Kettering Cancer Center Research Foundation of the City University of New York
A A A A A A
A61K A61K A61K A61P A61K A61K
inventional inventional inventional inventional inventional inventional
Jason S. Lynn Shashikanth Melissa
Lewis Francesconi Ponnala Deri